Market Place
Sourcing Support
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine
21 Sep 2024 //
PR NEWSWIRE
AbbVie Presents Solid Tumor Pipeline Data At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
Fulcrum Adds Chief Commercial Officer And Chief Regulatory Affairs Officer
19 Aug 2024 //
GLOBENEWSWIRE
AbbVie`s ovarian cancer therapy succeeds in mid-stage trial
07 Jun 2024 //
REUTERS
US FDA grants full approval to AbbVie`s ovarian cancer therapy
23 Mar 2024 //
REUTERS
FDA Grants Priority Review of ImmunoGen’s Supplemental BLA for ELAHERE
05 Dec 2023 //
BUSINESSWIRE
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
01 Dec 2023 //
REUTERS
ImmunoGen Announces EMA Acceptance of MAA for Mirvetuximab Soravtansine
27 Oct 2023 //
BUSINESSWIRE
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab in FR?+ Ovarian Cancer
01 Sep 2023 //
ONCLIVE
ELAHERE® Demonstrates 35% Reduction in the Risk of Death in Ovarian Cancer
04 Jun 2023 //
BUSINESSWIRE
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
05 May 2023 //
CLINICAL TRIALS ARENA
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial
03 May 2023 //
PRESS RELEASE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha
15 Nov 2022 //
MEDSCAPE
FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC
15 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
ImmunoGen Announces FDA Approval of ELAHERE for the Treatment of Ovarian Cancer
14 Nov 2022 //
BUSINESSWIRE
ImmunoGen Presents Updates for Mirvetuximab Soravtansine Combination Data
29 Sep 2022 //
BUSINESSWIRE
ImmunoGen Presents Analyses Evaluating Mirvetuximab Soravtansine
11 Sep 2022 //
BUSINESSWIRE
ImmunoGen Presents Efficacy and Safety Analyses of Mirvetuximab Soravtansine
26 May 2022 //
BUSINESSWIRE
ImmunoGen Submits BLA to FDA for Mirvetuximab Soravtansine in Ovarian Cancer
29 Mar 2022 //
BUSINESSWIRE
Immunogen`s phase 3 ADC survival data spook investors
22 Mar 2022 //
FIERCEBIOTECH
ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine
10 Mar 2022 //
PRESS RELEASE
Exceeding Expectations, ImmunoGen Eyes 2022 Approval for Ovarian Cancer Drug
01 Dec 2021 //
BIOSPACE
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA
29 Nov 2021 //
BUSINESSWIRE
AbbVie & Roche`s Venclexta scores another FDA OK; ImmunoGen nabs China deal
20 Oct 2020 //
ENDPTS
ImmunoGen and Huadong Medicine Announce Strategic Collaboration
19 Oct 2020 //
BUSINESSWIRE
ImmunoGen maps new path to accelerated approval
17 Dec 2019 //
ENDPT NEWS
ImmunoGen Announces Completion of Operational Review
27 Jun 2019 //
BIOSPACE
ImmunoGen cuts deep to eke out cash for mirvetuximab trial
27 Jun 2019 //
FIERCE BIOTECH
ImmunoGen drug fails cancer study, shares slide 40 percent
02 Mar 2019 //
REUTERS
Crunch time for ImmunoGen as phase 3 readout looms for lead ADC
01 Feb 2019 //
FIERCE BIOTECH
